BIOMAT Database Logo BIOMAT Database Logo

Application of comparative molecular field analysis to dopamine D2 partial agonists. 1999

G B McGaughey, and R E Mewshaw
Structural Biology and Global Chemical Sciences, Wyeth-Ayerst Research Laboratories, Princeton, NJ 08543-8000, USA.

Comparative molecular field analysis (CoMFA) has been applied to novel D2 partial agonists. Due to the predictability of the CoMFA model across different series of D2 partial agonists, we believe these compounds are binding to the D2 agonist receptor in the conformation and alignment described herein.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D017448 Receptors, Dopamine D2 A subfamily of G-PROTEIN-COUPLED RECEPTORS that bind the neurotransmitter DOPAMINE and modulate its effects. D2-class receptor genes contain INTRONS, and the receptors inhibit ADENYLYL CYCLASES. Dopamine D2 Receptors,Dopamine-D2 Receptor,D2 Receptors, Dopamine,Dopamine D2 Receptor,Receptor, Dopamine-D2

Related Publications

G B McGaughey, and R E Mewshaw
Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia.
May 2020, CNS drugs,
G B McGaughey, and R E Mewshaw
Serotonergic agonists behave as partial agonists at the dopamine D2 receptor.
February 1999, Neuroreport,
G B McGaughey, and R E Mewshaw
[A new approach to antischizophrenic therapeutics: D2 dopamine receptor partial agonists].
September 2009, Annales pharmaceutiques francaises,
G B McGaughey, and R E Mewshaw
Discovery of G Protein-Biased D2 Dopamine Receptor Partial Agonists.
December 2016, Journal of medicinal chemistry,
G B McGaughey, and R E Mewshaw
Reinforcing effects of D2 dopamine receptor agonists and partial agonists in rhesus monkeys.
October 2001, Drug and alcohol dependence,
G B McGaughey, and R E Mewshaw
Molecular electrostatic potential of D1 and D2 dopamine agonists.
January 1994, Journal of medicinal chemistry,
G B McGaughey, and R E Mewshaw
D2 receptor partial agonists: treatment of CNS disorders of dopamine function.
January 2008, Current topics in medicinal chemistry,
G B McGaughey, and R E Mewshaw
Partial brain dopamine D2 receptor agonists in the treatment of schizophrenia.
January 1989, Psychopharmacology bulletin,
G B McGaughey, and R E Mewshaw
Comparative molecular field analysis and molecular dynamics studies of the dopamine D2 receptor antagonists without a protonatable nitrogen atom.
January 2018, Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents,
G B McGaughey, and R E Mewshaw
D2 Dopamine Receptor G Protein-Biased Partial Agonists Based on Cariprazine.
May 2019, Journal of medicinal chemistry,
Copied contents to your clipboard!